J&J Gets CDSCO Panel Nod To Conduct Phase IV CT of Ustekinumab
New Delhi: In order to evaluate safety of Ustekinumab in Indian subjects with Crohn’s Disease (CD), pharmaceutical major, Johnson & Johnson has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV trial of Ustekinumab Pre-filled syringes 45 mg/0.5 ml, 90 mg/ml and Single use vial 130 mg/ 26 ml.
This came after the firm presented the protocol to conduct a Phase IV clinical trial titled “An Open Label, Multicenter, Phase IV Study of Ustekinumab to evaluate its safety in Indian subjects with Crohn’s Disease (CD)” vide protocol CNTO1275CRD4045".
After detailed deliberation, the committee recommended the approval of the presented Phase IV study protocol.
Also Read:Lupin Gets CDSCO Panel Nod for Phase IV CT of pulmonary FDC drug
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.